Iovance Biotherapeutics Inc at Jefferies Cell Therapy Summit Transcript
Well, welcome, everyone, to Jefferies Cell Therapy Summit. We're about almost done here on day 2. We've got Iovance Biotherapeutics, which has had, I guess, a news-filled last 12 hours. And so we've got CEO Maria Fardis to give us an overview of Iovance and I'm sure you'll give us the latest update. So Maria, please take it away.
Excellent. Thank you so much. Good afternoon. Thank you, Biren, for hosting us. I will be talking about investigating the power of tumor-infiltrating lymphocytes for treatment of cancers today. We're a public company. I draw your attention to our forward-looking statements.
In terms of recent updates, maybe I'll start with saying what information we have talked about in 2020 and then the latest update that we have provided to The Street yesterday. We've been talking about providing data in terms of -- we presented our melanoma data at ASCO as an oral presentation.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |